Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F-Y Lee

Showing results (351-360 of 355) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 355 results.
Leukemia|November 17, 2010
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemiaW-C Chou, W-C Lei, B-S Ko, et al.
Journal of Medicinal Chemistry|January 5, 1996
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activityK Leftheris, T Kline, G D Vite, et al.
Blood Cancer Journal|January 21, 2014
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndromeT-C Chen, H-A Hou, W-C Chou, et al.
Leukemia|August 10, 2013
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemiaH A Hou, C C Lin, W C Chou, et al.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Pageof 36

Showing results (351-360 of 355) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 355 results.
Leukemia|November 17, 2010
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemiaW-C Chou, W-C Lei, B-S Ko, et al.
Journal of Medicinal Chemistry|January 5, 1996
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activityK Leftheris, T Kline, G D Vite, et al.
Blood Cancer Journal|January 21, 2014
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndromeT-C Chen, H-A Hou, W-C Chou, et al.
Leukemia|August 10, 2013
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemiaH A Hou, C C Lin, W C Chou, et al.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Pageof 36